Eduardo Motti, MD

About Eduardo

Dr. Eduardo Motti serves as Chief Operating Officer of PHP Biotech and is one of the company’s most credentialed drug-development leaders, with more than 30 years spanning academic medicine, the global pharmaceutical industry, and clinical research operations.

Dr. Motti earned his medical degree from the University of São Paulo (USP) Medical School in 1978 and completed a residency and mastership in infectious diseases at USP, one of Latin America’s foremost medical institutions. After working extensively as a clinician, he moved into pharmaceutical development in 1984, beginning a 17-year tenure at Merck Sharp & Dohme. Over the following decades he held senior roles at Eurotrials, Schering AG (now Bayer), Pfizer — where he served as regional director of clinical operations for Latin America — and Aché Laboratories, building and leading multidisciplinary clinical research teams across Brazil and internationally.

In 2012 he founded Trials & Training, a consultancy supporting biopharmaceutical companies and academic organizations on clinical trial design, execution, and medical strategy. He is a certified executive coach, having completed his certification at Royal Roads University in Victoria, British Columbia, in 2013. Across his career Dr. Motti has contributed to more than 500 clinical research projects and has trained and mentored hundreds of healthcare professionals.

His expertise has been formally recognized: in 2020 he was named a Global Fellow in Medicines Development (GFMD) by the IFAPP Academy (International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine), part of the inaugural cohort of 117 fellows from 24 countries. He is also an active thought leader in the field, having authored commentary on ethics and inclusivity in clinical research for industry publications such as Clinical Leader.

At PHP Biotech, Dr. Motti’s role is to translate scientific promise into a disciplined clinical development plan — designing trials aligned with regulatory expectations, engaging the right CRO and CDMO partners, and building the operational infrastructure required to advance PHP53-nb into first-in-human studies. His combination of medical training, big-pharma leadership, and hands-on CRO experience makes him uniquely suited to guide that transition.